Long-Term Safety of Tofacitinib for Treatment of Moderate-to-Severe Ulcerative Colitis: Three Years of Korean National Data

Ulcerative colitis (UC) requires long-term treatment. Tofacitinib, a JAK inhibitor approved for UC, raises safety concerns regarding serious adverse events (SAEs) such as thromboembolism, major adverse cardiovascular events (MACEs), and opportunistic infections. This study aimed to evaluate the long...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Journal of Korean medical science Ročník 40; číslo 39; s. e259 - 9
Hlavní autori:	Song, Eun Mi, Seo, Gi Hyeon, Jung, Sung Hoon
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	Korea (South) 대한의학회 13.10.2025
Predmet:	Adult Aged Colitis, Ulcerative - drug therapy Colitis, Ulcerative - pathology Databases, Factual Female Herpes Zoster - epidemiology Humans Incidence Janus Kinase Inhibitors - adverse effects Janus Kinase Inhibitors - therapeutic use Male Middle Aged Piperidines - adverse effects Piperidines - therapeutic use Protein Kinase Inhibitors - adverse effects Protein Kinase Inhibitors - therapeutic use Pyrimidines - adverse effects Pyrimidines - therapeutic use Republic of Korea - epidemiology Risk Factors Severity of Illness Index Thromboembolism - epidemiology Thromboembolism - etiology Tumor Necrosis Factor Inhibitors - adverse effects Tumor Necrosis Factor Inhibitors - therapeutic use Young Adult 의학일반 Republic of Korea Cardiovascular Diseases Tofacitinib Ulcerative Colitis Infections Inflammatory Bowel Disease Safety Thromboembolism Korea
ISSN:	1011-8934, 1598-6357, 1598-6357
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!